| Name | Title | Contact Details |
|---|
Nexus operates 6 residential treatment sites with programming accredited by COA or TJC, and year-round, on-site schools, as well as inpatient psychiatric care programs, foster care and adoption, in-home counseling services, and ongoing support. Our programs offer a continuum of services to provide boys and girls a safe place to face their past and begin their future. We operate sites and services in Minnesota, Illinois, Maryland, North Dakota, and Idaho, each offering specialized treatment options for your child`s or adolescent`s needs. Mille Lacs Academy Gerard Academy Nexus Glen Lake Indian Oaks Academy Onarga Academy Woodbourne Center Kindred Family Focus PATH North Dakota PATH Idaho
Employee Development Corp is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trinity Home Care Products is a Rock Island, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acuity Healthcare is an employee-owned Long Term Acute Care (LTAC) hospital company, founded in 2001. Acuity is the only company with the flexibility to tailor its services to meet the specific needs of its clients. We understand how LTAC services can, and should work, within today`s "post-acute continuum". This innate flexibility and core understanding of the complexities of the healthcare continuum has enabled Acuity to develop a broad array of services that include: Joint Ventured ownership of its LTAC hospitals with area physicians and local hospitals, full LTAC contract management services, full LTAC contract financial management services and complete LTAC consulting services.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.